Tweet
Persons aged ≥65 years are at greater risk for hospitalization and death from seasonal influenza compared with other age groups,1,2 and they respond to vaccination with lower antibody titers to influenza hemagglutinin (an established correlate of protection against influenza) compared with younger adults.3 On December 23, 2009, the Food and Drug Administration (FDA) licensed an injectable inactivated trivalent influenza vaccine (Fluzone High-Dose, Sanofi-Pasteur) that contains an increased amount of influenza virus hemagglutinin antigen compared with other inactivated influenza vaccines such as Fluzone. Fluzone High-Dose is licensed as a single dose for use among persons aged ≥65 years and will be available beginning with the 2010-11 influenza season......
read entire paper at:
------------------------------------------------------------
Note that this paper says.."A 3-year postlicensure study of the vaccine effectiveness of Fluzone High-Dose compared with standard dose inactivated influenza vaccine (Fluzone) was begun in 2009 and should be completed in 2012"
So, we don't have efficacy data for this 4X normal vaccine. YET it is currently being administered (if you can find it)..
.
read entire paper at:
------------------------------------------------------------
Note that this paper says.."A 3-year postlicensure study of the vaccine effectiveness of Fluzone High-Dose compared with standard dose inactivated influenza vaccine (Fluzone) was begun in 2009 and should be completed in 2012"
So, we don't have efficacy data for this 4X normal vaccine. YET it is currently being administered (if you can find it)..
.